FTC To Investigate PBM Practices, Including Focus On Consumer Costs, Access
Executive Summary
Federal Trade Commission study of the six largest pharmacy benefit managers in the US wins the unanimous support of commissioners after its scope was broadened from an earlier version.
You may also be interested in...
FTC And PBMs: Support For Investigation Building But Outcome May Ultimately Disappoint Critics
Federal Trade Commission’s ‘pro-competitive’ perspective could support conclusion that pharmacy benefit managers serve useful role in lowering drug costs, health policy expert suggests. FTC will get an earful about PBM practices, but ‘those complaints could be an indication that competition is working.’
Senate Commerce Leaders Want An FTC Study Into PBM Business Practices – And More
Committee Chair Maria Cantwell (D-Wash.) solicits advice from witnesses for additional authorities to conduct oversight of PBMs and pushes for a GAO study.
A Case For Transparency: J&J Suit Targets Opaque PBM Affiliate’s Efforts To Exploit Copay Programs
Lawsuit highlights the lack of transparency into pharmacy benefit manager activities and how their programs can influence drug pricing. A Senate hearing on PBMs held shows increasing momentum behind a Federal Trade Commission study on potential anti-competitive activity in the market sector.